This trial is studying how well daratumumab, azacitidine, and dexamethasone work in treating patients with multiple myeloma that has come back or has not responded to treatment.
- Multiple Myeloma
1 Primary · 9 Secondary · Reporting Duration: Up to 18 months
1 Treatment Group
Treatment (azacitidine, dexamethasone, daratumumab)
1 of 1
5 Total Participants · 1 Treatment Group
Primary Treatment: Azacitidine · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How is Azacitidine most often employed therapeutically?
"ophthalmia, sympathetic is most commonly treated with Azacitidine. Azacitidine can also be useful for treating other conditions like complete blood count, induction chemotherapy, and branch retinal vein occlusion." - Anonymous Online Contributor
Can patients sign up for this research project at this time?
"The latest information from clinicaltrials.gov suggests that this study is still looking for test subjects. The first posting was on November 30th, 2020 and the page was updated as recently as August 9th, 2022." - Anonymous Online Contributor
Are there any dangers associated with taking Azacitidine?
"Azacitidine is a medication that, while having some evidence of safety from Phase 2 clinical trials, has not been proven effective." - Anonymous Online Contributor
How many test subjects are participating in this experiment?
"That is correct, the clinicaltrials.gov website contains current information about this study's status. The trial was first posted on 11/30/2020 and updated as recently as 8/9/2022. They are enrolling 23 participants at 1 site." - Anonymous Online Contributor